Normally, this protein is highly expressed during early development, but should gradually disappear when neurons mature and gain adult functions.
If called up later in life, TDP-43 is extremely toxic and can disable adult neurons within 3 weeks. By blocking its source of toxicity, nucleic acid binding, our drugs have the potential to simultaneously eliminate multiple pathological markers.
At Alteron Therapeutics, we are committed to developing first-in-class TDP-43 inhibitors to address the unmet needs of patients with neurodegenerative disorders and cystic fibrosis.
Our research pipeline focuses on advancing novel TDP-43 inhibitors through rigorous preclinical and clinical trials.
We actively seek collaborations with leading scientists and institutions to accelerate the development of groundbreaking therapies.
Unleashing the Power of Alteron's Medicines
Incubated and graduated from the Innovation Center in Western Michigan University School of Medicine
Efficacy study was performed by the Jackson Lab using an ALS mouse model expressing the wildtype human TDP-43 gene
Further advance the preclinical studies and file patents in national phases
Launching IND-enabling studies for ALTA-808 and IND filing